|
|
 |
|
|
|
|
 |
Soluble Triggering Receptor Expressed on Myeloid Cell-1 (sTREM-1): A New Mediator Involved in Early Ankylosing Spondylitis
CHUN-HSIUNG CHEN, HSIEN-TZUNG LIAO, HUNG-AN CHEN, TOONG-HUA LIANG, CHIN-TIEN WANG, and CHUNG-TEI CHOU
ABSTRACT. Methods. Serum sTREM-1 levels were measured in 80 patients with AS and 30 healthy controls, and synovial fluid (SF) sTREM-1 levels were tested in 6 AS patients using ELISA. Demographic data were collected, and patient's disease activity (BASDAI), functional ability (BASFI), and global assessment (BAS-G) were evaluated. We also tested erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and IgA in these patients. Results. Serum sTREM-1 levels were detectable (definition, ≥ 15 pg/ml) in 31.3% (25/80) of the AS patients, as compared to only 10% (3/30) of healthy controls (p = 0.027). SF sTREM-1 levels were detectable (≥ 15 pg/ml) in 83% (5/6) of the AS patients. The detectable rate of sTREM-1 in SF was significantly higher than in serum (p = 0.018). Disease duration was shorter in AS patients with "higher" serum sTREM-1 levels (≥ 30 pg/ml) versus those with "lower" levels (< 30 pg/ml) [mean (SD), 4.3 (3.7) vs 8.6 (7.8) yrs, p = 0.036], but the differences between these 2 groups of patients were not evident based on results of BASDAI, BASFI, BAS-G, ESR, CRP, or IgA levels. Of note, serum sTREM-1 levels inversely correlated with disease duration (r = –0.433, p = 0.03) in the 25 AS patients with detectable sTREM-1 levels. Conclusion. sTREM-1 seems to be a new mediator involved in patients with AS, particularly in the early stages of disease. (First Release July 15 2008; J Rheumatol 2008;35:1846-8) Key Indexing Terms:
ANKYLOSING SPONDYLITIS From the Institute of Clinical Medicine, National Yang-Ming University, and Veterans General Hospital-Taipei; and Buddhist Tzu Chi General Hospital, Taipei Branch, Taiwan. C-H. Chen, MD, Institute of Clinical Medicine, National Yang-Ming University, and Veterans General Hospital-Taipei, and Buddhist Tzu Chi General Hospital, Taipei Branch; H-T. Liao, MD, Institute of Clinical Medicine, National Yang-Ming University and Veterans General Hospital-Taipei, and Taipei Medical University—Municipal Wan Fang Hospital; H-A. Chen, MD, Institute of Clinical Medicine, National Yang-Ming University and Veterans General Hospital-Taipei; T-H. Liang, MD, Taipei Medical University—Municipal Wan Fang Hospital; C-T. Wang, PhD, Institute of Clinical Medicine, National Yang-Ming University and Veterans General Hospital-Taipei; C-T. Chou, MD, Institute of Clinical Medicine, National Yang-Ming University and Veterans General Hospital-Taipei. Address reprint requests to Dr. C-T. Chou, Division of Allergy-Immunology-Rheumatology, Veterans General Hospital-Taipei, No. 201, Sec. 2, ShiPai Road, Taipei, Taiwan 112. E-mail: ctchou@vghtpe.gov.tw Accepted for publication March 28, 2008. |
